Trials / Terminated
TerminatedNCT02438995
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Northwell Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intraarterial Cetxuimab (Erbitux) | Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2021-06-01
- Completion
- 2021-06-01
- First posted
- 2015-05-08
- Last updated
- 2021-11-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02438995. Inclusion in this directory is not an endorsement.